TERGURIDE / PROTERGURIDE FOR THE TREATMENT OF CHRONIC PAIN

Abstract

The present invention relates to the use of terguride and proterguride for the prophylaxis and/or the treatment of chronic pain conditions as well as to pharmaceutical compositions comprising terguride and/or proterguride optionally together with an opiate analgesic.

Description

Claims

1. Use of terguride or proterguride or a combination of terguride and proterguride or pharmacologically acceptable salts thereof for the preparation of a drug for the prophylaxis and/or the treatment of chronic pain or chronic pain conditions.

2. Use according to claim 1 for the treatment of persistent musculoskeletal pains and persistent visceral pains.

3. Use according to claim 2 for the treatment of persistent back pains, persistent neck pains, persistent shoulder pains, persistent joint pains and fibromyalgia.

4. Use according to claim 2 for the prophylaxis and the treatment of pains associated with premenstrual syndrome, mastalgia, stomach pain associated with irritable colon and pains associated with carcinoid syndrome.

5. Use according to claim 1 for the prophylaxis and the treatment of head pains and migraine.

6. Use according to claim 1 for the treatment of neuralgias, trigeminal neuralgia, postherpetic neuralgia, neuropathic pains and tumor associated pains.

7. Use according to claim 1 in combination with an opiate analgesic, dihydrocodeine, tramadol, morphine, morphine sulfate, oxycodone, methadone, hydromorphone, buprenorphine and fentanyl.

8. Pharmaceutical composition comprising terguride or proterguride or a combination of terguride and proterguride or their pharmacologically acceptable salts together with at least one pharmacologically acceptable carrier, auxiliary agent or solvent.

9. Pharmaceutical composition according to claim 8 suitable for inhalation or for intravenous, intraperitoneal, intramuscular, intravaginal, intrabuccal, percutaneous, subcutaneous, mucocutaneous, oral, peroral lumbar, rectal, transdermal, topical, intradermal, intragastric or intracutaneous administration.

10. Pharmaceutical composition according to claim 8 further comprising an active agent selected from the group comprising opiate analgesic, dihydrocodeine, tramadol, morphine, morphine sulfate, oxycodone, methadone, hydromorphone, buprenorphine and fentanyl.

11. Pharmaceutical composition according to claim 8 comprising terguride in the dose range of 0.1-3.0 mg per pharmaceutical formulation and/or proterguride in the dose range of 0.002-0.5 mg per pharmaceutical formulation.

12. Use according to claim 2 in combination with an opiate analgesic, dihydrocodeine, tramadol, morphine, morphine sulfate, oxycodone, methadone, hydromorphone, buprenorphine and fentanyl.

13. Use according to claim 3 in combination with an opiate analgesic, dihydrocodeine, tramadol, morphine, morphine sulfate, oxycodone, methadone, hydromorphone, buprenorphine and fentanyl.

14. Use according to claim 4 in combination with an opiate analgesic, dihydrocodeine, tramadol, morphine, morphine sulfate, oxycodone, methadone, hydromorphone, buprenorphine and fentanyl.

15. Use according to claim 5 in combination with an opiate analgesic, dihydrocodeine, tramadol, morphine, morphine sulfate, oxycodone, methadone, hydromorphone, buprenorphine and fentanyl.

16. Use according to claim 6 in combination with an opiate analgesic, dihydrocodeine, tramadol, morphine, morphine sulfate, oxycodone, methadone, hydromorphone, buprenorphine and fentanyl.

17. Pharmaceutical composition according to claim 9 further comprising an active agent selected from the group comprising opiate analgesic, dihydrocodeine, tramadol, morphine, morphine sulfate, oxycodone, methadone, hydromorphone, buprenorphine and fentanyl.

18. Pharmaceutical composition according to claim 9 comprising terguride in the dose range of 0.1-3.0 mg per pharmaceutical formulation and/or proterguride in the dose range of 0.002-0.5 mg per pharmaceutical formulation.

19. Pharmaceutical composition according to claim 10 comprising terguride in the dose range of 0.1-3.0 mg per pharmaceutical formulation and/or proterguride in the dose range of 0.002-0.5 mg per pharmaceutical formulation.

20. Pharmaceutical composition according to claim 17 comprising terguride in the dose range of 0.1-3.0 mg per pharmaceutical formulation and/or proterguride in the dose range of 0.002-0.5 mg per pharmaceutical formulation.